Table 3.
Oncological outcomes
| ART group (n = 22) | Non-ART group (n = 146) | |
|---|---|---|
| DFS event, n (%) | ||
| No | 20 (90.9) | 106 (72.6) |
| Yes | 2 (9.1) | 40 (27.4) |
| DFS type, n (%) | ||
| Locoregional recurrence of primary invasive breast cancer | 2 (9.1) | 7 (4.8) |
| Distant recurrence (with or without locoregional recurrence) of primary invasive breast cancer | 0 (–) | 10 (6.9) |
| Second primary breast cancer | 0 (–) | 19 (13.0) |
| Second primary malignancy | 0 (–) | 4 (2.7) |
| Death without recurrence | 0 (–) | 0 (–) |
| Death, n (%) | ||
| No | 22 (100.0) | 136 (93.1) |
| Yes | 0 (–) | 10 (6.9) |
| Median follow-up from breast cancer diagnosis, years (IQR) | 7.5 (6.5-10.5) | 8.8 (6.8-11.8) |
| Median time from breast cancer diagnosis to DFS event, years (IQR) | 7.5 (6.5-10.5) | 7.9 (5.6-10.5) |
| Median follow-up from conception, years (IQR) | 3.4 (1.1-5.5) | 5.0 (2.8-7.7) |
| Median time from conception to DFS event, years (IQR) | 3.4 (1.1-5.3) | 3.7 (2.0-6.1) |
ART, assisted reproductive techniques; DFS, disease-free survival; IQR, interquartile range.